Head and Neck Squamous Cell Carcinoma: KOL Insight
Immunotherapies are about to transform HNSCC treatment. Can one brand corner the market?
Key opinion leaders (KOLs) say immunotherapies will transform head and neck squamous cell carcinoma (HNSCC) treatment. But until Phase III trial results are in, no one knows exactly where these promising new drugs will fit into the treatment algorithm—and whether any one brand can corner the market.
Find out what KOLs think in FirstWord’s new report, KOL Insight: HNSCC
You’ll find out how immunotherapies are likely to be used, how they’ll affect current treatments, and whether they’ll face competition from targeted agents in the pipeline. You’ll also get KOLs’ candid thoughts on the important clinical trials shaping HNSCC treatment and prescribing.